Transient Elastography Changes on Patient with Hepatic Cirhossis who were Treated by Simvastatin 20  Mg Compared to Simvastatin 10 mg

Endro tanoyo; Neneng Ratnasari; Sutanto Maduseno

doi:10.22146/actainterna.61292

Transient Elastography Changes on Patient with Hepatic Cirhossis who were Treated by Simvastatin 20 Mg Compared to Simvastatin 10 mg

https://doi.org/10.22146/actainterna.61292

Endro tanoyo^(1*), Neneng Ratnasari⁽²⁾, Sutanto Maduseno⁽³⁾

(1)
(2)
(3)
(*) Corresponding Author

Abstract

Background. Liver cirrhosis is a pathological condition that describes the end stage of liver fibrosis. Fibrosis is currently a two-way process. The process of returning from fibrosis now is a clinical reality. According to Abraldes et al. (2009), administration of simvastatin for one month will increase liver cell regeneration and improve endothelial dysfunction. Liver biopsy is still the gold standard for assessing liver cirrhosis, but this procedure is invasive and has the potential to cause life-threatening complications. Liver biopsy is complicated by sampling errors (reaching 30%) and different abilities between observers. Transient elastography (Fibro scan) is a non-invasive modality for diagnosing liver fibrosis that has high sensitivity and specificity.

Aim. The aim of the study was to discover the difference in effect, of simvastatin 20 mg compared to 10 mg for 3 months to improve liver stiffness in patients with liver cirrhosis.

Method. The study design used a double blind, randomized clinical trial. The subjects of the study consisted of a group given simvastatin 10 mg / day and the group given simvastatin 20 mg / day for 3 months. Routine medications for cirrhosis were still made according to the original dose. During the study, an initial and final transient elastography examination was carried out and monthly supervision of medication compliance and side effects. Data analysis for statistical tests was carried out by t-test, Mann Whitney test, fisher’s-exact test, and ANOVA test.

Result. A total of 21 subjects underwent thorough research and transient elastography. The simvastatin 10mg group (n = 12) experienced a decrease in liver stiffness, with a delta mean of liver stiffness of -4.97+7.09 (p <0.023) compared to the simvastatin 20 mg group (n = 9) with a heart stiffness of -4.09 + 10.06 (p= 0.982). Changed liver stiffness in the two groups were not statistically significant differences. Etiology and confounding drugs showed statistically no significant effect.

Conclusion. Both simvastatin 10 mg and 20 mg can reduce liver stiffness. The effect of the two doses of the drug in reducing liver stiffness was not statistically significant different.

Keywords

Cirrhosis of the liver, simvastatin, fibro scan, transient elastography

Full Text:

PDF

References

Nurdjanah S., 2009. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, et al. (eds) Buku Ajar Ilmu Penyakit Dalam. Edisi V Jilid I. Hal:668-673. Jakarta. Interna Publishing.

Garcia-tsao, G., & Lim, J., 2009. Management and Treatment of Patients With Cirrhosis and Portal Hypertension : Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Nature ;104(7): 1802–1829.

Starr, S. P., Raines, D., State, L., Orleans, N., & Orleans, N., 2011. Cirrhosis: Diagnosis, Management, and Prevention; Am. Fam. Physician; 4(12):1353–9.

Zhou, W., Zhang, Q., & Qiao, L., 2014. Pathogenesis of liver cirrhosis. World J Gastroenterol; 20(23): 7312–7324.

Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A., 2014. R p Liver fibrosis and repair : immune regulation of wound healing in a solid organ. Nature Publishing Group.14(3):181–194.

Lakner, A. M., Steuerwald, N. M., Walling, T. L., Ghosh, S., Li, T., … Schrum, L. W., 2012. Inhibitory Effects of MicroRNA 19b in Hepatic Stellate Cell-Mediated Fibrogenesis. Official Journal of AASLD; 14891: 1–11.

Oakley, F., Meso, M., Iredale, J. P., Mann, D. A., 2005. Inhibition of Inhibitor of kappaB Kinases Stimulates Hepatic Stellate Cell Apoptosis and Accelerated Recovery From Rat Liver Fibrosis. Gastroenterology;128(1):108–120,

Cadranel, J-F., Rufat, P., Doges, F. 2000. Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey. Hepatology Vol. 32, No. 3: 477-481

Mueller, S. and Sandrin, L. 2010. Liver stiffness: a novel parameter for the diagnosisn of liver disease. Hepatic Medicine: Evidence and Research ;2: 49–67

Hashemi, S.A., Lavian, S.M., dan Gholami-Fesharaki, M. 2016. Assessment of Transient Elastography (Fibroscan) For Diagnosis Of Fibrosis In Non-Alcoholic Fatty Liver Disease: A Systematic Review

and Meta-Analysis. Caspian J Intern Med ; 7(4): 242-252.

Abraldes, J. G., Albillos, A., Bañares, R., Turnes, J., & González, R., 2009. Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal. YGAST. 136(5): 1651–1658,

Schuppan, D., Afdhal, N. H., & Israel, B., 2008. Seminar Liver cirrhosis. Lancet; 371: 838–51

Kumar, S., Grace, N. D., Qamar, A. A. 2014. Statin Use in Patients with Cirrhosis : A Retrospective Cohort Study. Dig Dis Sci; 59:1958–1965.

Gea, V.H., Friedman, S.L.2011. The Annual Review of Pathology: Pathogenesis of Liver Fibrosis. Annu. Rev. Pathol. Mech. Dis; 6:425–56.

Marrone, G., Maeso-díaz, R., Garcíacardena, G., Abraldes, J. G., Garcíapagán, J. C., Bosch, J., & Gracia-sancho,J., 2014. KLF2 exerts anti fibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut;0:1–10.

Prabowo, N, A. 2015. Pengaruh simvastatin terhadap kadar transforming Growth factor β1, skor fibroscan dan skor aspartat Transaminase to platelet index Pada pasien sirosis hati. Universitas Negeri Surakarta. Tersedia dari: https://digilib.uns.ac.id.

Kemp, W. and Robert, S. 2013. Fibroscan and Transient Elastography. Aust.Fam. Physician; 42(7):468-71.

Perazzo, H., Veloso, V, G., Griesztejn, B., Hyde, C., & Castro, R. 2015. Factors That Could Impact on Liver Fibrosis Staging by Transient Elastography. International Journal of Hepatology Vol 2015: 1-4.

Faber, J., & Fonseca, L. M. 2014. How Sample Size Influences Research Outcomes. Dental Press J Orthod;19(4):27-9.

Sporea, I., Srili, R., Deleanu, A., Tudora, A., Popescu, A., Curescu, M., & Bota, S. 2010. Liver Stiffness Measurements In Patients With Hbv Vs Hcv Chronic Hepatitis: A Comparative Study. World J Gastroenterol; 16(38): 4832-4837

Cecchi, F., Mannoni, A., Molino-Lova, R., Ceppatelli, S., Benvenuti, E., Bandinelli, S., Lauretani, F., Macchi, C., Ferrucci, L. 2008. Epidemiology Of Hip And Knee Pain In A Community Based Sample Of Italian Persons Aged 65 And Older. Osteoarthritis Cartilage ; 16(9): 1039–1046.

Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers MF, et al. 2000. Systemic risk factors for osteoarthritis. In: Felson conference chair DT, Ed. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med; 133:637–9.

Golomb, B.A. and Evans, M.A. 2008. Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism. Am J Cardiovasc Drugs ; 8(6): 373–418.

Pieri, G., Agarwal, B., & Burroughs, A.K. 2014. C-Reactive Protein And Bacterial Infection In Cirrhosis. Ann Gastroenterol; 27 (2): 113-120

Quinaglia e Silva, J.C., Munhoz, D.B., Morato, T.N., Gurgel, A., Macedo, A.C.T., Sever, P., Sposito, A.C.2009. Effect of beta blockers (metoprolol or propranolol) on effect of Simvastatin in lowering c-reactive protein in Acute myocardial infarction. Am.J. Cardiol;103:461– 463.

Badiu, R., Bucsa, C., Mogosan, C., Dumitrascu, D. 2016. Statin Drug-Drug Interactions In A Romanian CommunityPharmacy. Clujul Medical Vol. 89 no. 2:273-278

Setoguchi, S., Higgins, J.M., Mogun, H.,Mootha, V.K., Avorn, J. 2010. Propanolol and the Risk of hospitalized Myopathy :Translating Chemical genomics Findings into Population-Level Hypotheses. Am Heart J. 2010 Mar;159 (3):428-33.

DOI: https://doi.org/10.22146/actainterna.61292